Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Drops By 26.2%

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest totaling 1,816,131 shares, a decrease of 26.2% from the February 26th total of 2,460,745 shares. Based on an average trading volume of 1,893,138 shares, the days-to-cover ratio is presently 1.0 days. Currently, 6.9% of the company’s stock are sold short.

MAIA Biotechnology Stock Performance

MAIA remained flat at $1.31 during trading on Monday. The company had a trading volume of 538,107 shares, compared to its average volume of 1,348,822. The stock has a market cap of $79.48 million, a PE ratio of -1.90 and a beta of -0.04. MAIA Biotechnology has a 52-week low of $0.87 and a 52-week high of $3.19. The firm’s fifty day moving average price is $1.91 and its 200-day moving average price is $1.57.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Monday, March 23rd. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. On average, equities research analysts expect that MAIA Biotechnology will post -1.3 EPS for the current year.

Institutional Investors Weigh In On MAIA Biotechnology

A number of large investors have recently bought and sold shares of the business. Marshall Wace LLP bought a new position in MAIA Biotechnology during the second quarter valued at about $29,000. Ritholtz Wealth Management bought a new stake in shares of MAIA Biotechnology during the 4th quarter worth about $35,000. Jane Street Group LLC bought a new stake in shares of MAIA Biotechnology during the 2nd quarter worth about $52,000. Geode Capital Management LLC increased its holdings in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after acquiring an additional 7,746 shares during the last quarter. Finally, Centric Wealth Management increased its holdings in shares of MAIA Biotechnology by 2.0% during the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock valued at $897,000 after acquiring an additional 11,500 shares during the last quarter. 5.65% of the stock is currently owned by institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.